Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, Apellis Pharmaceuticals, Inc. (APLS) has a Wall Street consensus price target of $33.50, based on estimates from 25 covering analysts. With the stock currently trading at $20.96, this represents a potential upside of +59.8%. The company has a market capitalization of $2.65B.
Analyst price targets range from a low of $19.00 to a high of $52.00, representing a 99% spread in expectations. The median target of $30.50 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 18 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, APLS trades at a trailing P/E of 116.4x.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $20.96, with bear and bull scenarios of $-488.55 and $17.67 respectively. Model confidence stands at 30/100, suggesting limited visibility into future performance.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how APLS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for APLS is $33.5, representing 59.8% upside from the current price of $20.96. With 25 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
APLS has a consensus rating of "Buy" based on 25 Wall Street analysts. The rating breakdown is predominantly bullish, with 18 Buy/Strong Buy ratings. The consensus 12-month price target of $33.5 implies 59.8% upside from current levels.
APLS's current price is $20.96 with a consensus target of $33.5 (59.8% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $52 for APLS, while the most conservative target is $19. The consensus of $33.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $18 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
APLS is heavily covered by Wall Street, with 25 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 17 have Buy ratings, 6 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month APLS stock forecast based on 25 Wall Street analysts shows a consensus price target of $33.5, with estimates ranging from $19 (bear case) to $52 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $21, with bear/bull scenarios of $-489/$18.
Our quantitative valuation model calculates APLS's fair value at $21 (base case), with a bear case of $-489 and bull case of $18. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 30/100.
Wall Street analysts are very optimistic on APLS, with a "Buy" consensus rating and $33.5 price target (59.8% upside). 18 of 25 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
APLS analyst price targets range from $19 to $52, a 99% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $33.5 consensus represents the middle ground. Our model's $-489-$18 range provides an independent fundamental perspective.